Ovensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer.
The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ovensa.com
- Keywords
- Precision & Combination Medicines, Peptide Therapeutics, Immuno-Oncology Therapeutics, CNS Therapeutics, DNA & RNA Based Therapeutics, Tumor Microenvironment Modulation, Targeted Conjugation & Multi-Combination Product Designs, Nano Conjugates, Nanoparticles, Brain Targeting, Extracellular & Intracellular Targeting, Non Lipidic & Non Viral.
Ovensa Inc. Questions
Ovensa Inc.'s website is ovensa.com
Ovensa Inc.'s LinkedIn profile is https://ca.linkedin.com/company/ovensa
Ovensa Inc. has
2 employees.
View email and phone details for 2
employees at Ovensa Inc..
Ovensa Inc.'s industry is
Biotechnology Research
Ovensa Inc.'s categories are Biotechnology Research
Ovensa Inc.'s founding year is 2012
